Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: a systematic review and meta-analysis
Y Higashimoto, M Ando, A Sano, S Saeki… - Respiratory …, 2020 - Elsevier
Pulmonary rehabilitation (PR) is recommended as an effective treatment for patients with
chronic obstructive pulmonary disease (COPD). Previous meta-analyses showed that PR …
chronic obstructive pulmonary disease (COPD). Previous meta-analyses showed that PR …
Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
…, S Iyama, T Jodai, K Akaike, S Ishizuka, S Saeki… - Cancer immunology …, 2020 - AACR
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
…, S Hamada, S Iyama, K Saruwatari, S Saeki… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia
…, H Kishi, K Fujii, K Fukuda, Y Tomita, S Saeki… - Respiratory …, 2021 - Elsevier
Background In December 2019, the coronavirus disease (COVID-19), caused by the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and …
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and …
[HTML][HTML] Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies
…, S Ishizuka, N Sato, K Saruwatari, S Saeki… - Journal of clinical …, 2019 - mdpi.com
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …
in immune-related adverse events. Recent case studies have suggested the association …
[HTML][HTML] Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer …
…, K Nishino, O Hataji, K Ota, N Ebi, S Saeki… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors
may confer an improved response for non–small cell lung cancer (NSCLC). However, …
may confer an improved response for non–small cell lung cancer (NSCLC). However, …
TGFβ signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma
R Sato, K Imamura, T Semba, Y Tomita, S Saeki… - Cancer Research, 2021 - AACR
CAFs secrete TGFβ to induce a solid-to-acinar transition in lung cancer cells, demonstrating
how the tumor microenvironment influences histological patterns and tumor heterogeneity in …
how the tumor microenvironment influences histological patterns and tumor heterogeneity in …
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
K Tanaka, K Chamoto, S Saeki, R Hatae… - Science Translational …, 2022 - science.org
Despite the success of cancer immunotherapies such as programmed cell death–1 (PD-1)
and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination …
and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination …
[HTML][HTML] Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small …
…, H Okabayashi, K Saruwatari, Y Tomita, S Saeki… - BMC pulmonary …, 2019 - Springer
Background Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of …
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of …
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti‐PD‐1 immune checkpoint antibody in a lung cancer patient
…, T Kimura, K Saruwatari, S Saeki… - Immunity …, 2019 - Wiley Online Library
Introduction The impact of immune checkpoint blockade on immunity in cancer patients is
not completely elucidated due to the complexity of the immune network. Recent studies have …
not completely elucidated due to the complexity of the immune network. Recent studies have …